Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019
Since the first biosimilar medicine, Omnitrope<sup>®</sup> (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System (NHS) over the period betw...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
MDPI AG,
2021-04-01T00:00:00Z.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Izan zaitez lehena ohar bat uzten!